

Pronounced differences between native Chinese and Sw
polymorphic hydroxylations of debrisoquin and S-mep

Clinical Pharmacology and Therapeutics

51, 388-397

DOI: 10.1038/clpt.1992.38

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Genetically Determined Polymorphisms in Drug Metabolism. Journal of Pharmacy Practice, 1992, 5, 317-336. | 0.5 | 0 |
| 2 | Genetic polymorphisms in drug metabolism. Journal of Internal Medicine, 1992, 231, 571-573. | 2.7 | 5 |
| 3 | Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clinical Pharmacology and Therapeutics, 1993, 53, 410-418. | 2.3 | 153 |
| 4 | Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?. Clinical Pharmacology and Therapeutics, 1993, 53, 608-610. | 2.3 | 35 |
| 5 | Polymorphism of Debrisoquine and Mephenytoin Hydroxylation among Estonians. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 113-115. | 0.0 | 13 |
| 6 | Pharmacokinetics of R(+)-Terodiline Given Intravenously and Orally to Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 1993, 73, 153-158. | 0.0 | 7 |
| 7 | Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations. European Journal of Clinical Pharmacology, 1993, 44, 593-595. | 0.8 | 16 |
| 8 | Variations in Drug Metabolism Due to Genetic Polymorphism. Drug Investigation, 1993, 5, 19-34. | 0.6 | 13 |
| 9 | Molecular basis of drug oxidation polymorphisms. Nordic Journal of Psychiatry, 1993, 47, 27-31. | 0.7 | 0 |
| 10 | Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, The, 1993, 341, 63. | 6.3 | 192 |
| 11 | Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.. British Journal of Clinical Pharmacology, 1993, 36, 105-108. | 1.1 | 37 |
| 12 | Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11825-11829. | 3.3 | 612 |
| 13 | Future Directions for Pharmacogenetics. Journal of Pharmacy Practice, 1993, 6, 44-46. | 0.5 | 0 |
| 14 | Recent Developments in Drug Metabolism of Relevance to Psychiatrists. Harvard Review of Psychiatry, 1994, 2, 204-213. | 0.9 | 62 |
| 15 | Disposition of Clozapine and Desmethylclozapine in Schizophrenic Patients. Journal of Clinical Pharmacology, 1994, 34, 318-324. | 1.0 | 27 |
| 16 | Effect of Levomepromazine and Metabolites on Debrisoquine Hydroxylation in the Rat. Basic and Clinical Pharmacology and Toxicology, 1994, 75, 255-260. | 0.0 | 7 |
| 17 | Drug metabolizing enzymes related to laboratory medicine: Cytochromes P-450 and UDP-glucuronosyltransferases. Clinica Chimica Acta, 1994, 226, 171-190. | 0.5 | 27 |
| 18 | Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.. British Journal of Clinical Pharmacology, 1994, 37, 71-74. | 1.1 | 87 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Frequency of human CYP2D6 mutant alleles in a normal Chinese population.. British Journal of Clinical Pharmacology, 1994, 37, 605-607. | 1.1 | 25 |
| 20 | Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6—an evaluation with the nonparametric maximum likelihood method.. British Journal of Clinical Pharmacology, 1994, 38, 453-462. | 1.1 | 36 |
| 21 | Dapsone N-acetylation, metoprolol \pm -hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trial. Clinical Pharmacology and Therapeutics, 1994, 56, 142-153. | 2.3 | 27 |
| 23 | Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clinical Pharmacology and Therapeutics, 1994, 56, 176-183. | 2.3 | 56 |
| 24 | Intra- and Interethnic Variability in Reduced Haloperidol to Haloperidol Ratios. Journal of Clinical Pharmacology, 1995, 35, 128-136. | 1.0 | 23 |
| 25 | Recent Advances: the Cytochrome P450 Enzymes. Annals of Pharmacotherapy, 1995, 29, 619-624. | 0.9 | 238 |
| 26 | Interethnic difference in omeprazole's inhibition of diazepam metabolism*. Clinical Pharmacology and Therapeutics, 1995, 58, 62-72. | 2.3 | 67 |
| 27 | Genetic analysis of the S-mephenytoin polymorphism in a chinese population*. Clinical Pharmacology and Therapeutics, 1995, 58, 404-411. | 2.3 | 126 |
| 28 | Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*. Clinical Pharmacology and Therapeutics, 1995, 58, 29-34. | 2.3 | 25 |
| 29 | Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation*. Clinical Pharmacology and Therapeutics, 1995, 58, 155-164. | 2.3 | 74 |
| 30 | Cytochrome P4502D6 genotype does not determine response to clozapine.. British Journal of Clinical Pharmacology, 1995, 39, 417-420. | 1.1 | 65 |
| 31 | Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.. British Journal of Clinical Pharmacology, 1995, 39, 511-518. | 1.1 | 169 |
| 32 | Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients. Psychiatry Research, 1995, 57, 101-108. | 1.7 | 4 |
| 33 | Pharmacogenetics in clinical pharmacology and toxicology. Canadian Journal of Physiology and Pharmacology, 1995, 73, 331-338. | 0.7 | 26 |
| 34 | Drug Interactions and the Cytochrome P450 System. Clinical Pharmacokinetics, 1995, 29, 45-52. | 1.6 | 73 |
| 35 | Active Hydroxymetabolites of Antidepressants. Clinical Pharmacokinetics, 1995, 28, 26-40. | 1.6 | 52 |
| 36 | Emergency Treatment of Psychotic Symptoms. Clinical Pharmacokinetics, 1995, 28, 494-504. | 1.6 | 180 |
| 37 | Geographical/Interracial Differences in Polymorphic Drug Oxidation. Clinical Pharmacokinetics, 1995, 29, 192-209. | 1.6 | 380 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 38 | Clinical Pharmacokinetics and Metabolism of Chloroquine. <i>Clinical Pharmacokinetics</i> , 1996, 31, 257-274. | 1.6 | 253 |
| 39 | Pharmacokinetic Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 1996, 31, 372-385. | 1.6 | 26 |
| 40 | Polymorphic Drug Oxidation. <i>CNS Drugs</i> , 1996, 5, 200-223. | 2.7 | 124 |
| 41 | Evaluating the Clinical Significance of Drug Interactions: A Systematic Approach. <i>Harvard Review of Psychiatry</i> , 1996, 4, 153-158. | 0.9 | 20 |
| 42 | Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. <i>Digestive Diseases and Sciences</i> , 1996, 41, 475-479. | 1.1 | 37 |
| 43 | Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1996, 21, 129-138. | 0.6 | 76 |
| 44 | Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. <i>European Journal of Clinical Pharmacology</i> , 1996, 51, 117-122. | 0.8 | 63 |
| 45 | Debrisoquin and Sâ€Mephenytoin Hydroxylation Phenotypes and CYP2D6 Genotypes in an Estonian Population. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 303-307. | 0.0 | 11 |
| 46 | Antidepressants and drugâ€™metabolizing enzymes â€™ expert group report. <i>Acta Psychiatrica Scandinavica</i> , 1996, 93, 71-79. | 2.2 | 63 |
| 47 | Psychiatry, psychopharmacology and P-450s. <i>Human Psychopharmacology</i> , 1996, 11, 97-114. | 0.7 | 36 |
| 48 | Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. <i>Biomedical Applications</i> , 1996, 677, 178-182. | 1.7 | 18 |
| 49 | Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. <i>Biomedical Applications</i> , 1996, 678, 113-128. | 1.7 | 73 |
| 50 | The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 423-428. | 2.3 | 90 |
| 51 | Ethnic and genetic determinants of omeprazole disposition and effect*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 157-167. | 2.3 | 62 |
| 52 | Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 183-190. | 2.3 | 120 |
| 53 | Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 396-404. | 2.3 | 49 |
| 54 | Ropivacaine gel in active distal ulcerative colitis and proctitisâ€™a pharmacokinetic and exploratory clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 73-81. | 1.9 | 53 |
| 55 | Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 175-179. | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 56 | Smoking among Chinese Patients with Schizophrenia. Australian and New Zealand Journal of Psychiatry, 1996, 30, 350-353. | 1.3 | 44 |
| 57 | Genetic Polymorphisms in Human Drug-Metabolizing Enzymes: Potential Uses of Reverse Genetics to Identify Genes of Toxicological Relevance. Critical Reviews in Toxicology, 1997, 27, 199-222. | 1.9 | 52 |
| 58 | Novel Approaches to Drug Delivery in Critical Care. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 65-78. | 0.8 | 1 |
| 59 | The Molecular Epidemiology of Lung Cancer. Critical Reviews in Toxicology, 1997, 27, 319-365. | 1.9 | 82 |
| 60 | Debilitating Reaction following the Initial Dose of Tramadol. Annals of Pharmacotherapy, 1997, 31, 1150-1152. | 0.9 | 29 |
| 61 | CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Canadian Journal of Physiology and Pharmacology, 1997, 75, 165-172. | 0.7 | 15 |
| 62 | In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans. Clinical Drug Investigation, 1997, 13, 37-46. | 1.1 | 64 |
| 63 | Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clinical Pharmacokinetics, 1997, 32, 210-258. | 1.6 | 641 |
| 64 | Genetic Polymorphism of Drug Metabolising Enzymes in African Populations: Implications for the Use of Neuroleptics and Antidepressants. Brain Research Bulletin, 1997, 44, 561-571. | 1.4 | 84 |
| 65 | Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clinical Chemistry, 1997, 43, 254-266. | 1.5 | 153 |
| 66 | A Combination of Mutations in the <i>CYP2D6*17</i> (<i>CYP2D6Z</i>) Allele Causes Alterations in Enzyme Function. Molecular Pharmacology, 1997, 52, 1034-1040. | 1.0 | 134 |
| 67 | Age Might Influence the Frequency Distribution of Metoprolol Hydroxylation Polymorphism in a Chinese Population. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 167-170. | 0.0 | 2 |
| 68 | Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatrica Scandinavica, 1997, 96, 14-21. | 2.2 | 84 |
| 69 | Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. European Journal of Clinical Pharmacology, 1997, 53, 257-260. | 0.8 | 15 |
| 70 | Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism. British Journal of Clinical Pharmacology, 1997, 44, 239-244. | 1.1 | 6 |
| 71 | The effect of paroxetine on thiothixene pharmacokinetics. Journal of Clinical Pharmacy and Therapeutics, 1997, 22, 221-226. | 0.7 | 4 |
| 72 | Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects*. Clinical Pharmacology and Therapeutics, 1997, 62, 129-137. | 2.3 | 103 |
| 73 | Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin*. Clinical Pharmacology and Therapeutics, 1997, 62, 384-391. | 2.3 | 85 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 74 | 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 444-452. | 2.3 | 281 |
| 75 | CYP2D6 polymorphism is not crucial for the disposition of selegiline*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 402-411. | 2.3 | 23 |
| 76 | Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 529-539. | 2.3 | 121 |
| 77 | Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 484-491. | 2.3 | 72 |
| 78 | Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 469-474. | 0.8 | 27 |
| 79 | Genetic polymorphism of CYP2D6 in North Indian subjects. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 787-791. | 0.8 | 29 |
| 80 | High-performance liquid chromatography-mass spectrometry for the quantification of nortriptyline and 10-hydroxynortriptyline in plasma. <i>Biomedical Applications</i> , 1998, 716, 382-386. | 1.7 | 16 |
| 81 | Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 384-390. | 2.3 | 79 |
| 82 | CYP2C19 Genotype and Phenotype Determined with Omeprazole in Patients with Acid-Related Disorders with and without <i>Helicobacter pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1034-1038. | 0.6 | 22 |
| 83 | Ritonavir. <i>Clinical Pharmacokinetics</i> , 1998, 35, 275-291. | 1.6 | 423 |
| 84 | Inhibition and Induction of Cytochrome P450 and the Clinical Implications. <i>Clinical Pharmacokinetics</i> , 1998, 35, 361-390. | 1.6 | 674 |
| 85 | Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 403-416. | 0.7 | 164 |
| 86 | Determination of drug-metabolizing enzyme activity in vivo : pharmacokinetic and statistical issues. <i>Xenobiotica</i> , 1998, 28, 1255-1273. | 0.5 | 36 |
| 87 | Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. <i>International Journal of Neuropsychopharmacology</i> , 1998, 1, 173-185. | 1.0 | 27 |
| 88 | Optimizing Drug Therapy Based on Genetic Differences: Implications for the Clinical Setting. <i>AACN Advanced Critical Care</i> , 1998, 9, 499-512. | 1.9 | 4 |
| 89 | Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 161-170. | 0.7 | 27 |
| 90 | Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene. <i>CNS Spectrums</i> , 1999, 4, 30-34, 47-56. | 0.7 | 17 |
| 91 | Frequencies of Defective CYP2C19 Alleles in a Hong Kong Chinese Population: Detection of the Rare Allele CYP2C19*4. <i>Clinical Chemistry</i> , 1999, 45, 2273-2274. | 1.5 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 92 | Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 27-36. | 1.9 | 362 |
| 93 | Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 453-458. | 1.9 | 37 |
| 94 | Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 395-401. | 1.1 | 55 |
| 95 | Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 145-150. | 1.1 | 21 |
| 96 | Cytochrome P450 2D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians. <i>European Journal of Neurology</i> , 1999, 6, 323-329. | 1.7 | 11 |
| 97 | Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 7-16. | 0.7 | 82 |
| 98 | Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 87-92. | 0.7 | 92 |
| 99 | Gender-related differences in pharmacokinetics and their clinical significance. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 339-346. | 0.7 | 237 |
| 100 | Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 516-521. | 2.3 | 27 |
| 101 | Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 275-282. | 2.3 | 44 |
| 102 | Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major genotypes. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 402-407. | 2.3 | 60 |
| 103 | Polymorphic cytochromes P450 and drugs used in psychiatry. <i>Cellular and Molecular Neurobiology</i> , 1999, 19, 325-354. | 1.7 | 43 |
| 104 | Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment. <i>Cellular and Molecular Neurobiology</i> , 1999, 19, 309-323. | 1.7 | 55 |
| 105 | Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 185-192. | 2.3 | 111 |
| 106 | Polymorphism of dextromethorphan oxidation in South Indian subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 193-200. | 2.3 | 9 |
| 107 | Genetic Polymorphisms of Human N-Acetyltransferase, Cytochrome P450, Glutathione-S-Transferase, and Epoxide Hydrolase Enzymes: Relevance to Xenobiotic Metabolism and Toxicity. <i>Critical Reviews in Toxicology</i> , 1999, 29, 59-124. | 1.9 | 279 |
| 108 | Psychotropic medications and HIV medicine: A rational approach. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999, 3, 229-236. | 1.2 | 1 |
| 109 | Human cytochromes P450. <i>Molecular Aspects of Medicine</i> , 1999, 20, 1-137. | 2.7 | 196 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 110 | Pharmacogenetics in the practice of laboratory medicine. <i>Molecular Diagnosis and Therapy</i> , 1999, 4, 365-379. | 1.3 | 27 |
| 111 | Pharmacokinetics of Haloperidol. <i>Clinical Pharmacokinetics</i> , 1999, 37, 435-456. | 1.6 | 208 |
| 112 | Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1495-1502. | 1.9 | 32 |
| 113 | CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1259-1266. | 1.9 | 127 |
| 114 | Pharmacogenetics and psychopharmacotherapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 197-220. | 0.7 | 182 |
| 115 | Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 567-576. | 2.3 | 57 |
| 116 | Genotype and phenotype of cytochrome P 450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 231-240. | 0.8 | 34 |
| 117 | THE RELEVANCE OF ETHNIC INFLUENCES ON PHARMACOGENETICS TO THE TREATMENT OF PSYCHOSIS. <i>Drug Metabolism and Drug Interactions</i> , 2000, 16, 15-38. | 0.3 | 27 |
| 118 | Genetic variations of S-mephenytoin 4-hydroxylase (CYP2C19) in the chinese population. <i>Life Sciences</i> , 2000, 66, PL175-PL181. | 2.0 | 21 |
| 119 | Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. <i>Gastroenterology</i> , 2000, 119, 670-676. | 0.6 | 84 |
| 120 | MOLECULAR BASIS OF ETHNIC DIFFERENCES IN DRUG DISPOSITION AND RESPONSE. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 815-850. | 4.2 | 552 |
| 121 | P-Hydroxylation of Phenobarbital: Relationship to (s)-Mephenytoin Hydroxylation (CYP2C19) Polymorphism. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 115-118. | 1.0 | 29 |
| 122 | Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 477-487. | 5.7 | 90 |
| 123 | Evaluation of CYP2D6 Oxidation of Dextromethorphan and Propafenone in a Chinese Population with Atrial Fibrillation. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 92-96. | 1.0 | 13 |
| 124 | The Effect of CYP2C19 and CYP2D6 Genotypes on the Metabolism of Clomipramine in Japanese Psychiatric Patients. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 549-555. | 0.7 | 35 |
| 125 | Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. <i>Psychiatric Genetics</i> , 2001, 11, 153-155. | 0.6 | 12 |
| 126 | Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 793-803. | 1.9 | 104 |
| 127 | Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 107-108. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 128 | Heterogeneity of the CYP2D6 gene among Malays in Malaysia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 205-211. | 0.7 | 45 |
| 129 | Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 265-271. | 1.1 | 66 |
| 130 | Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoinS/R enantiomeric ratio in urine measured by chiral GC. <i>Biomedical Chromatography</i> , 2001, 15, 9-13. | 0.8 | 9 |
| 131 | CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 333-339. | 2.3 | 67 |
| 132 | Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 42-47. | 2.3 | 126 |
| 133 | Polymorphism of drug metabolizing enzymes in humans. <i>Sepsis</i> , 2001, 4, 247-254. | 0.5 | 4 |
| 134 | Codeine phosphate in paediatric medicine. <i>British Journal of Anaesthesia</i> , 2001, 86, 413-421. | 1.5 | 143 |
| 135 | Antidepressant Drug Interactions. <i>Journal of Pharmacy Practice</i> , 2001, 14, 467-477. | 0.5 | 3 |
| 136 | The pharmacogenomics of depression. <i>Pharmacogenomics Journal</i> , 2001, 1, 175-177. | 0.9 | 13 |
| 137 | Cytochrome P450 2D6 Genotyping and Association with Tardive Dyskinesia in Chinese Schizophrenic Patients. <i>Pharmacopsychiatry</i> , 2001, 34, 238-241. | 1.7 | 38 |
| 138 | Metabolism Profiling, and Cytochrome P450 Inhibition & Induction in Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2001, 1, 403-425. | 1.0 | 174 |
| 139 | Metabolism of 18-Methoxycoronaridine, an Ibogaine Analog, to 18-Hydroxycoronaridine by Genetically Variable CYP2C19. <i>Drug Metabolism and Disposition</i> , 2002, 30, 663-669. | 1.7 | 19 |
| 140 | Inhibition Kinetics of Monoclonal Antibodies against Cytochromes P450. <i>Drug Metabolism and Disposition</i> , 2002, 30, 701-708. | 1.7 | 15 |
| 141 | Slower Metabolism and Reduced Intake of Nicotine From Cigarette Smoking in Chinese-Americans. <i>Journal of the National Cancer Institute</i> , 2002, 94, 108-115. | 3.0 | 192 |
| 142 | Cytochrome P450 polymorphisms and response to antipsychotic therapy. <i>Pharmacogenomics</i> , 2002, 3, 201-218. | 0.6 | 51 |
| 143 | Pharmacogenomics of Major Depression and Antidepressant Treatment. , 0, , 379-395. | | 0 |
| 144 | Proton pump inhibitors - differences emerge in hepatic metabolism. <i>Digestive and Liver Disease</i> , 2002, 34, 461-467. | 0.4 | 65 |
| 145 | Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics. <i>Clinical Pharmacokinetics</i> , 2002, 41, 453-470. | 1.6 | 141 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 146 | Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. <i>Clinical Pharmacokinetics</i> , 2002, 41, 913-958. | 1.6 | 771 |
| 147 | CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. <i>Pharmacogenomics</i> , 2002, 3, 229-243. | 0.6 | 696 |
| 148 | Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bupropion, and Debrisoquine. <i>Drug Metabolism and Disposition</i> , 2002, 30, 595-601. | 1.7 | 56 |
| 149 | Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies. <i>Journal of Clinical Oncology</i> , 2002, 20, 3683-3690. | 0.8 | 262 |
| 150 | Clinical relevance of the CYP2D6 polymorphism for the treatment of psychiatric disorders. <i>International Congress Series</i> , 2002, 1244, 11-20. | 0.2 | 1 |
| 151 | Analysis of the CYP2D6 gene in relation to its metabolic capacity in Japanese men and in comparison with other populations. <i>International Congress Series</i> , 2002, 1244, 33-39. | 0.2 | 0 |
| 152 | Genetic polymorphism of CYP2C19 in Chinese ethnic populations. <i>International Congress Series</i> , 2002, 1244, 51-61. | 0.2 | 4 |
| 153 | CYP2C pharmacogenetics and tailor-made therapeutic implications. <i>International Congress Series</i> , 2002, 1244, 1-9. | 0.2 | 4 |
| 154 | Single-Step Assays to Analyze CYP2D6 Gene Polymorphisms in Asians: Allele Frequencies and a Novel *14B Allele in Mainland Chinese. <i>Clinical Chemistry</i> , 2002, 48, 983-988. | 1.5 | 89 |
| 155 | Pharmacogenetics of psychotropic drug metabolism. , 2002, , 157-180. | | 3 |
| 157 | Reduced ($\hat{\pm}$)-3,4-methylenedioxymethamphetamine ($\hat{\pm}$ Ecstasy $\hat{\pm}$) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. <i>Biochemical Pharmacology</i> , 2002, 63, 2111-2119. | 2.0 | 57 |
| 158 | Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 111-122. | 1.1 | 456 |
| 159 | Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. <i>Pharmacogenomics Journal</i> , 2002, 2, 400-407. | 0.9 | 33 |
| 160 | Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 192-199. | 2.3 | 33 |
| 161 | Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 253-263. | 2.3 | 174 |
| 162 | Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 385-388. | 0.8 | 25 |
| 163 | The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 517-528. | 2.3 | 131 |
| 164 | Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. <i>Toxicology</i> , 2003, 183, 151-173. | 2.0 | 104 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 165 | Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 279-284. | 0.7 | 18 |
| 166 | Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H ₂ -receptor antagonist. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 1149-1157. | 1.9 | 27 |
| 167 | Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 14-22. | 1.1 | 5 |
| 168 | Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 630-634. | 1.1 | 13 |
| 169 | Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 415-421. | 1.1 | 79 |
| 170 | Polymorphisms and the Pocketbook: The Cost-Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of <i>Helicobacter pylori</i> Infection Associated with Duodenal Ulcer. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1316-1323. | 1.0 | 27 |
| 171 | Inheritance and Drug Response. <i>New England Journal of Medicine</i> , 2003, 348, 529-537. | 13.9 | 961 |
| 172 | PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1255-1259. | 1.7 | 77 |
| 173 | Pharmacokinetic/Pharmacodynamic Modeling of the Antinociceptive Effects of (+)-Tramadol in the Rat: Role of Cytochrome P450 2D Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 710-718. | 1.3 | 47 |
| 174 | Bioinformatics Research on Inter-racial Difference in Drug Metabolism I. Analysis on Frequencies of Mutant Alleles and Poor Metabolizers on CYP2D6 and CYP2C19. <i>Drug Metabolism and Pharmacokinetics</i> , 2003, 18, 48-70. | 1.1 | 98 |
| 175 | The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 169-175. | 0.7 | 17 |
| 176 | A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 943-967. | 1.0 | 124 |
| 177 | Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 207-218. | 5.7 | 66 |
| 178 | Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1083-1105. | 1.0 | 193 |
| 179 | Cytochrome P-450 2D6*10 C188T Polymorphism Is Associated with Antipsychotic-Induced Persistent Tardive Dyskinesia in Chinese Schizophrenic Patients. <i>Neuropsychobiology</i> , 2004, 49, 167-173. | 0.9 | 45 |
| 180 | Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers. <i>Clinical Chemistry</i> , 2004, 50, 1623-1633. | 1.5 | 126 |
| 181 | Omeprazole Treatment of Korean Patients: Effects on Gastric pH and Gastrin Release in Relation to CYP2C19 Geno- and Phenotypes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 95, 112-119. | 0.0 | 9 |
| 182 | Pharmacogenomics: bench to bedside. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 739-748. | 21.5 | 293 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 183 | Determination of Dextromethorphan and Dextrorphan in Human Urine by High Performance Liquid Chromatography for Pharmacogenetic Investigations. <i>Chromatographia</i> , 2004, 59, . | 0.7 | 6 |
| 184 | Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. <i>European Journal of Clinical Pharmacology</i> , 2004, 59, 803-807. | 0.8 | 149 |
| 185 | Fatal intoxication cases: cytochrome P 450 2D6 and 2C19 genotype distributions. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 547-552. | 0.8 | 33 |
| 186 | Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates. <i>Drug Metabolism Reviews</i> , 2004, 36, 243-277. | 1.5 | 111 |
| 187 | Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. <i>Pharmacological Research</i> , 2004, 50, 195-200. | 3.1 | 190 |
| 188 | Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes. <i>Drug Safety</i> , 2004, 27, 145-172. | 1.4 | 92 |
| 189 | Genetic Predictors of the Clinical Response to Opioid Analgesics. <i>Clinical Pharmacokinetics</i> , 2004, 43, 983-1013. | 1.6 | 230 |
| 190 | Cardiovascular Pharmacogenetics. <i>Handbook of Experimental Pharmacology</i> , 2004, , . | 0.9 | 0 |
| 191 | Nonlinear Mixed Effects Model Analysis of the Pharmacokinetics of Metoprolol in Routinely Treated Japanese Patients. <i>Biological and Pharmaceutical Bulletin</i> , 2004, 27, 1642-1648. | 0.6 | 29 |
| 192 | Influence of CYP2D6 Genotype on Metoprolol Plasma Concentration and β -Adrenergic Inhibition During Long-Term Treatment. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 713-720. | 0.8 | 55 |
| 193 | Bench to Bedside: Pharmacogenomics, Adverse Drug Interactions, and the Cytochrome P450 System. <i>Academic Emergency Medicine</i> , 2005, 12, 1227-1235. | 0.8 | 29 |
| 194 | The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 69-75. | 1.1 | 23 |
| 195 | Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. <i>Chirality</i> , 2005, 17, 338-344. | 1.3 | 19 |
| 196 | Dextromethorphan metabolic phenotyping in an Iranian population. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 849-854. | 0.8 | 12 |
| 197 | CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 749-754. | 0.8 | 47 |
| 198 | Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 491-497. | 0.8 | 59 |
| 199 | Acid-Suppressive Efficacy of a Reduced Dosage of Rabeprazole: Comparison of 10 Mg Twice Daily Rabeprazole with 20 Mg Twice Daily Rabeprazole, 30 Mg Twice Daily Lansoprazole, and 20 Mg Twice Daily Omeprazole by 24-Hr Intragastric pH-metry. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1202-1206. | 1.1 | 16 |
| 201 | A Comparative Study of the Efficacy and Safety Profiles Between Fluvoxamine and Nortriptyline in Japanese Patients with Major Depression. <i>Pharmacopsychiatry</i> , 2005, 38, 30-35. | 1.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 202 | Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7342-7349. | 0.8 | 43 |
| 203 | EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF LORATADINE IN CHINESE SUBJECTS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1283-1287. | 1.7 | 23 |
| 204 | Treatment in risperidone-induced amenorrhoea. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 29-34. | 1.2 | 7 |
| 205 | Pharmacogenomics: Historical Perspective and Current Status. , 2005, 311, 003-016. | | 14 |
| 207 | Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. <i>Annual Review of Genomics and Human Genetics</i> , 2006, 7, 223-245. | 2.5 | 203 |
| 209 | Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance. <i>Drug Safety</i> , 2006, 29, 735-768. | 1.4 | 89 |
| 210 | Possible Interethnic Differences in Omeprazole Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2006, 45, 593-610. | 1.6 | 12 |
| 211 | The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 486-491. | 2.5 | 36 |
| 212 | The Use of Wireless Laptop Computers for Computer-Assisted Learning in Pharmacokinetics. <i>American Journal of Pharmaceutical Education</i> , 2006, 70, 04. | 0.7 | 10 |
| 213 | Potential Interactions of Methylphenidate and Atomoxetine with Dextromethorphan. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2006, 46, 472-478. | 0.7 | 7 |
| 214 | Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 060606032707078-??? | 1.4 | 13 |
| 215 | Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 144-152. | 2.3 | 47 |
| 216 | Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 621-625. | 0.8 | 21 |
| 217 | Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 107-112. | 0.8 | 43 |
| 218 | Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 681-691. | 1.1 | 7 |
| 219 | Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges. <i>Harvard Review of Psychiatry</i> , 2006, 14, 92-108. | 0.9 | 26 |
| 220 | Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. <i>Pharmacological Reviews</i> , 2006, 58, 521-590. | 7.1 | 379 |
| 221 | Pharmacogenomics: Bench to Bedside. <i>Focus (American Psychiatric Publishing)</i> , 2006, 4, 431-441. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 222 | Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance. <i>Journal of Pharmacy Practice</i> , 2007, 20, 206-218. | 0.5 | 32 |
| 223 | Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy. <i>Current Drug Metabolism</i> , 2007, 8, 109-136. | 0.7 | 54 |
| 224 | Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism. <i>Current Pharmaceutical Design</i> , 2007, 13, 241-250. | 0.9 | 18 |
| 225 | Clinical Pharmacogenetics. , 2007, , 179-195. | | 2 |
| 226 | CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6â€“serotoninâ€“dopamine crosstalk revisited. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 339-347. | 0.7 | 39 |
| 227 | Determination of Amphetamine, Methamphetamine, and Hydroxyamphetamine Derivatives in Urine by Gas Chromatography-Mass Spectrometry and Its Relation to CYP2D6 Phenotype of Drug Users. <i>Journal of Analytical Toxicology</i> , 2007, 31, 31-36. | 1.7 | 25 |
| 228 | Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy. <i>CNS Drugs</i> , 2007, 21, 143-164. | 2.7 | 40 |
| 229 | Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 606-609. | 2.3 | 80 |
| 230 | Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 353-363. | 0.7 | 4 |
| 231 | Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 517-524. | 0.7 | 30 |
| 232 | CYP2C19 Polymorphism in Korean patients on warfarin therapy. <i>Archives of Pharmacal Research</i> , 2007, 30, 344-349. | 2.7 | 18 |
| 233 | Which Has Superior Acid-Suppressive Effect, 10 Mg Omeprazole Once Daily or 20 Mg Famotidine Twice Daily? Effects of Single or Repeated Administration in Japanese Helicobacter Pylori-Negative CYP2C19 Extensive Metabolizers. <i>Digestive Diseases and Sciences</i> , 2007, 52, 390-395. | 1.1 | 5 |
| 234 | Genetic polymorphism of CYP2C19 in Maharashtrian population. <i>European Journal of Epidemiology</i> , 2007, 22, 907-915. | 2.5 | 21 |
| 235 | Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 141-156. | 0.8 | 18 |
| 236 | The Implications of Population Admixture in Race-based Drug Prescription. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 399-400. | 2.3 | 11 |
| 237 | The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 234-242. | 2.3 | 650 |
| 238 | Actual and Potential Drug Interactions Associated with Methadone. <i>Pain Medicine</i> , 2008, 9, 315-344. | 0.9 | 83 |
| 239 | A Systematic Review of Opioid Conversion Ratios Used with Methadone for the Treatment of Pain. <i>Pain Medicine</i> , 2008, 9, 595-612. | 0.9 | 92 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 240 | CYP2D6 phenotypes among Malays in Malaysia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 25, 379-383. | 0.7 | 0 |
| 241 | Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 567-573. | 0.7 | 37 |
| 242 | Role of cytochrome P450 in drug interactions. <i>Nutrition and Metabolism</i> , 2008, 5, 27. | 1.3 | 138 |
| 243 | Sex-specific differences in CYP450 isoforms in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 413-424. | 1.5 | 137 |
| 244 | Pharmacogenomics and Personalized Medicine. , 2008, , 211-223. | | 4 |
| 245 | Handbook of Drug Monitoring Methods. , 2008, , . | | 13 |
| 246 | Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 110, 56-66. | 1.2 | 35 |
| 247 | Drug-Drug Interactions, Second Edition. , 0, , . | | 8 |
| 248 | Paranoid Psychosis and Myoclonus: Flecainide Toxicity in Renal Failure. <i>Cardiology</i> , 2008, 111, 83-86. | 0.6 | 22 |
| 249 | Chapter 22 Pharmacogenomics for forensic toxicology in enabling personalized medicine. <i>Handbook of Analytical Separations</i> , 2008, 6, 745-761. | 0.8 | 2 |
| 250 | Evaluation of a [¹³ C]â€Dextromethorphan Breath Test to Assess CYP2D6 Phenotype. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1041-1051. | 1.0 | 31 |
| 251 | Clinical Pharmacogenetics and Potential Application in Personalized Medicine. <i>Current Drug Metabolism</i> , 2008, 9, 738-784. | 0.7 | 196 |
| 252 | Personalized Medicine: Pharmacogenetics in Psychiatry. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2008, 6, 1-11. | 0.2 | 3 |
| 253 | Pharmacogenetics of ethnic populations. , 0, , 62-86. | | 2 |
| 254 | Identification of New CYP2C19 Variants Exhibiting Decreased Enzyme Activity in the Metabolism of S-Mephenytoin and Omeprazole. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2262-2269. | 1.7 | 38 |
| 255 | Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 2661-2805. | 1.2 | 64 |
| 256 | Opioid Metabolism. <i>Mayo Clinic Proceedings</i> , 2009, 84, 613-624. | 1.4 | 537 |
| 257 | CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. <i>Pharmacogenomics Journal</i> , 2009, 9, 175-184. | 0.9 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 258 | Medicinal Chemistry Strategies to Reduce CYP2D6 Inhibitory Activity of Lead Candidates. <i>Current Medicinal Chemistry</i> , 2009, 16, 3093-3121. | 1.2 | 13 |
| 259 | Rapid and slow hydroxylators of seminal E prostaglandins among men in barren unions. <i>Andrologia</i> , 1995, 27, 71-79. | 1.0 | 11 |
| 260 | Opioid Metabolism and Effects of Cytochrome P450. <i>Pain Medicine</i> , 2009, 10, S20-S29. | 0.9 | 67 |
| 261 | Polymorphism of human cytochrome P450 enzymes and its clinical impact. <i>Drug Metabolism Reviews</i> , 2009, 41, 89-295. | 1.5 | 671 |
| 262 | Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2009, 12, 334-361. | 2.9 | 96 |
| 263 | Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. <i>Clinical Pharmacokinetics</i> , 2009, 48, 689-723. | 1.6 | 604 |
| 264 | Opioid switching and rotation in primary care: implementation and clinical utility. <i>Current Medical Research and Opinion</i> , 2009, 25, 2133-2150. | 0.9 | 65 |
| 265 | The Influence of Genetic Polymorphisms on Population Variability in Six Xenobiotic-Metabolizing Enzymes. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2009, 12, 307-333. | 2.9 | 39 |
| 266 | Ethnic differences in drug metabolism and toxicity from chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 243-257. | 1.5 | 106 |
| 267 | Opioid Metabolism. <i>Mayo Clinic Proceedings</i> , 2009, 84, 613-624. | 1.4 | 354 |
| 269 | Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 929-940. | 1.0 | 189 |
| 270 | Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 269-273. | 0.8 | 12 |
| 271 | CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 871-877. | 0.8 | 53 |
| 272 | Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma: application to a human pharmacokinetic study. <i>Biomedical Chromatography</i> , 2010, 24, 1113-1119. | 0.8 | 6 |
| 273 | Pharmacogenomics: a systems approach. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2010, 2, 3-22. | 6.6 | 55 |
| 274 | High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 354-359. | 2.3 | 113 |
| 275 | Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. <i>Pharmacogenomics</i> , 2010, 11, 537-546. | 0.6 | 107 |
| 276 | CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 29-41. | 1.5 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 277 | Estimation of the Interindividual Variability of Cytochrome 2D6 Activity from Urinary Metabolic Ratios in the Literature. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 243-253. | 1.1 | 19 |
| 278 | Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an Indian population perspective. <i>Arzneimittelforschung</i> , 2010, 60, 12-21. | 0.5 | 5 |
| 279 | Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1â€fyear after renal transplantation. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 208-216. | 0.7 | 12 |
| 280 | Influence of <i>ABCB1</i> genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with <i>CYP2D6</i> *10/*10. <i>British Journal of Pharmacology</i> , 2011, 164, 433-443. | 2.7 | 41 |
| 281 | Update on the pharmacogenomics of proton pump inhibitors. <i>Pharmacogenomics</i> , 2011, 12, 873-888. | 0.6 | 80 |
| 282 | Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model. <i>AAPS Journal</i> , 2011, 13, 390-404. | 2.2 | 22 |
| 283 | Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. <i>Archives of Pharmacal Research</i> , 2011, 34, 1817-1828. | 2.7 | 16 |
| 284 | Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 55-67. | 1.1 | 171 |
| 285 | Ethnopsychopharmacology considerations for Asians and Asian Americans. <i>Asian Journal of Psychiatry</i> , 2012, 5, 18-23. | 0.9 | 9 |
| 286 | Clinical Pharmacogenetics. , 2012, , 195-215. | | 0 |
| 287 | Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 102-108. | 0.3 | 36 |
| 288 | Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study. <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 324-331. | 1.1 | 3 |
| 290 | Relative bioavailability and pharmacokinetic comparison of two different enteric formulations of omeprazole. <i>Journal of Zhejiang University: Science B</i> , 2012, 13, 348-355. | 1.3 | 16 |
| 291 | Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group. <i>Chirality</i> , 2012, 24, 289-293. | 1.3 | 9 |
| 292 | The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 991-997. | 1.1 | 25 |
| 293 | Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?. <i>Wiener Medizinische Wochenschrift</i> , 2012, 162, 252-261. | 0.5 | 6 |
| 294 | Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 43-51. | 0.6 | 5 |
| 295 | Oxidoreductase Inhibitors. , 2013, , 641-696. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 296 | Genetics of Population Differences in Drug Response. <i>Current Genetic Medicine Reports</i> , 2013, 1, 162-170. | 1.9 | 40 |
| 297 | Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population. <i>Gene</i> , 2013, 527, 360-365. | 1.0 | 14 |
| 298 | Cytochrome P450 genetic polymorphisms of Mexican indigenous populations. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 193-208. | 0.3 | 15 |
| 299 | Pharmacogenomics in Drug Metabolizing Enzymes and Transporters. , 2013, , 1095-1123. | | 0 |
| 300 | How Personalized Medicine Became Genetic, and Racial: Werner Kalow and the Formations of Pharmacogenetics. <i>Journal of the History of Medicine and Allied Sciences</i> , 2013, 68, 1-48. | 0.1 | 28 |
| 301 | Drug Metabolism and Pharmacogenetics. , 2013, , 58-69. | | 0 |
| 302 | Metoprolol oxidation polymorphism in Brazilian elderly cardiac patients. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 1347-1353. | 1.2 | 6 |
| 303 | Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review. <i>Journal of Pharmacogenomics & Pharmacoproteomics</i> , 2013, 05, . | 0.2 | 0 |
| 304 | Options for treating postherpetic neuralgia in the medically complicated patient. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 329. | 0.9 | 16 |
| 305 | A Systematically Combined Genotype and Functional Combination Analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in Different Geographic Areas of Mainland China – A Basis for Personalized Therapy. <i>PLoS ONE</i> , 2013, 8, e71934. | 1.1 | 8 |
| 306 | Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. <i>Oman Medical Journal</i> , 2013, 28, 237-244. | 0.3 | 16 |
| 307 | A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS. , 2014, 64, 9.18.1-9.18.10. | | 1 |
| 309 | Pathophysiology and principles of management of the many faces of the acute vasoocclusive crisis in patients with sickle cell disease. <i>European Journal of Haematology</i> , 2015, 95, 113-123. | 1.1 | 29 |
| 310 | Increasing use of “party drugs”™ in people living with HIV on antiretrovirals. <i>Aids</i> , 2015, 29, 1585-1592. | 1.0 | 85 |
| 311 | Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model. <i>Drug Metabolism and Disposition</i> , 2015, 43, 870-883. | 1.7 | 18 |
| 312 | Cytochrome P450 in Cancer Susceptibility and Treatment. <i>Advances in Clinical Chemistry</i> , 2015, 71, 77-139. | 1.8 | 81 |
| 313 | Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 549-567. | 0.8 | 166 |
| 314 | Opioid Analgesics and Nicotine: More Than Blowing Smoke. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2015, 29, 281-289. | 0.5 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 315 | Treatment of <i>Helicobacter Pylori</i> infection: optimization strategies in a high resistance era. Expert Opinion on Pharmacotherapy, 2015, 16, 2307-2317. | 0.9 | 14 |
| 316 | Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica, 2015, 45, 256-263. | 0.5 | 7 |
| 317 | The Promise of Psychiatric Pharmacogenomics. Biological Psychiatry, 2015, 77, 29-35. | 0.7 | 49 |
| 318 | Factors affecting the development of adverse drug reactions to β -blockers in hospitalized cardiac patient population. Patient Preference and Adherence, 2016, Volume 10, 1461-1469. | 0.8 | 9 |
| 319 | The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1303-1311. | 1.5 | 4 |
| 320 | CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients. Pharmacogenomics, 2016, 17, 1295-1304. | 0.6 | 0 |
| 321 | CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients. Breast Journal, 2016, 22, 54-62. | 0.4 | 19 |
| 322 | CYP2C19 drug-drug and drug-gene interactions in ED patients. American Journal of Emergency Medicine, 2016, 34, 245-249. | 0.7 | 7 |
| 323 | Interethnic variation of CYP2C19 alleles, \hat{c} -predicted \hat{c} ™ phenotypes and \hat{c} -measured \hat{c} ™ metabolic phenotypes across world populations. Pharmacogenomics Journal, 2016, 16, 113-123. | 0.9 | 114 |
| 324 | Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 179-185. | 1.0 | 6 |
| 325 | Study on inter-ethnic human differences in bioactivation and detoxification of estragole using physiologically based kinetic modeling. Archives of Toxicology, 2017, 91, 3093-3108. | 1.9 | 9 |
| 326 | Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population. Expert Review of Clinical Pharmacology, 2017, 10, 1145-1152. | 1.3 | 3 |
| 327 | Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphicism in South Indian population with clopidogrel therapy. International Journal of Cardiology, 2017, 229, 113-118. | 0.8 | 11 |
| 328 | Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS/MS and Real Time-PCR methods. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1047, 173-179. | 1.2 | 12 |
| 330 | Genetic variation of cytochrome P450 in Uyghur Chinese population. Drug Metabolism and Pharmacokinetics, 2018, 33, 55-60. | 1.1 | 3 |
| 331 | Selected Food/Herb-Drug Interactions: Mechanisms and Clinical Relevance. American Journal of Therapeutics, 2018, 25, e423-e433. | 0.5 | 24 |
| 332 | Pharmacogenomics in and its Influence on Pharmacokinetics. , 2018, , 1-28. | | 0 |
| 333 | The Role of Cytochromes P450 in Infection. Frontiers in Immunology, 2018, 9, 89. | 2.2 | 103 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 334 | Genomics and Drug-Metabolizing Enzymes and Its Application in Drug Delivery: Evaluating the Influence of the Microbiome. , 2018, , 177-200. | | 0 |
| 335 | Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis. <i>Mycoses</i> , 2019, 62, 969-978. | 1.8 | 5 |
| 336 | Pharmacogenomics in Psychiatric Disorders. , 2019, , 181-225. | | 0 |
| 338 | Different treatment efficacies and side effects of cytotoxic chemotherapy. <i>Journal of Thoracic Disease</i> , 2020, 12, 3785-3795. | 0.6 | 13 |
| 339 | Major CYP450 Polymorphism among Saudi Patients. <i>Drug Metabolism Letters</i> , 2021, 14, 17-24. | 0.5 | 3 |
| 340 | CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. <i>Archives of Toxicology</i> , 2021, 95, 2867-2870. | 1.9 | 2 |
| 341 | Herb-drug interactions and toxicity: Underscoring potential mechanisms and forecasting clinically relevant interactions induced by common phytoconstituents via data mining and computational approaches. <i>Food and Chemical Toxicology</i> , 2021, 156, 112432. | 1.8 | 10 |
| 342 | Pharmacogenomics of Endocrine Therapy in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 630, 220-231. | 0.8 | 20 |
| 343 | CYP2D6 phenotypes among Malays in Malaysia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 379-383. | 0.7 | 7 |
| 344 | <i>CYP2D6</i> Basic Genotyping of Patients with Chronic Pain Receiving Tramadol or Codeine. A Study in a Greek Cohort. <i>Pain Medicine</i> , 2020, 21, 3199-3204. | 0.9 | 5 |
| 345 | Pharmacokinetics of Clozapine and Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 177-187. | 0.7 | 94 |
| 346 | Multiple-Dose Pharmacokinetics of Clozapine in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 470-476. | 0.7 | 37 |
| 347 | Pronounced Differences in the Disposition of Clomipramine Between Japanese and Swedish Patients. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 393-400. | 0.7 | 27 |
| 348 | Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 472-475. | 0.7 | 28 |
| 349 | Steady-State Plasma Levels of Nortriptyline and Its Hydroxylated Metabolites in Japanese Patients: Impact of CYP2D6 Genotype on the Hydroxylation of Nortriptyline. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 141-149. | 0.7 | 54 |
| 350 | Monitoring of Plasma Clozapine Levels and Its Metabolites in Refractory Schizophrenic Patients. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 200-207. | 1.0 | 59 |
| 351 | Intraindividual and Interindividual Variability in the Disposition of the Local Anesthetic Ropivacaine in Healthy Subjects. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 126-131. | 1.0 | 42 |
| 352 | High-Dose Omeprazole: Use of a Multiple-Dose Study Design to Assess Bioequivalence and Accuracy of CYP2C19 Phenotyping. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 526. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 355 | " Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial". Annals of Gastroenterology, 2017, 31, 205-210. | 0.4 | 12 |
| 356 | The Study on CYP2D6*10 In Vivo and In Vitro.. Drug Metabolism and Pharmacokinetics, 2000, 15, 165-170. | 0.0 | 3 |
| 357 | Treating Depression: Potential Drug Interactions. Psychiatric Annals, 1997, 27, 244-258. | 0.1 | 10 |
| 358 | Review of Opioid-Associated Hearing Loss and Possible Mechanism of Opioid-Mediated Endothelin-1-Dependent Cochlear Vasoconstriction. Journal of Otology & Rhinology, 2014, 03, . | 0.1 | 4 |
| 359 | Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive. International Journal of Clinical Pharmacology and Therapeutics, 2006, 44, 605-613. | 0.3 | 9 |
| 360 | Frequency Distribution of Cytochrome P450 2C19 Genotypes in a Korean Population. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2002, 10, 40. | 0.1 | 0 |
| 361 | The Role of Pharmacokinetics in Drug Development. , 2002, , 280-313. | | 0 |
| 362 | The Role of Pharmacokinetics in Drug Development. , 2002, , . | | 0 |
| 363 | Genetic Polymorphisms and Cardiovascular Drug Metabolism. Handbook of Experimental Pharmacology, 2004, , 39-77. | 0.9 | 2 |
| 364 | Pharmacogenetics of Drug Metabolism. Drugs and the Pharmaceutical Sciences, 2005, , 51-69. | 0.1 | 0 |
| 365 | Pharmacogenomics in DME. , 2006, , 721-735. | | 0 |
| 366 | Influence of 5-HT _{3B} Receptor AAG Deletion Mutation and CYP2D6*10 on the Ondansetron Treatment. Daehan Macwi'gwa Haghoeji, 2006, 50, 84. | 0.2 | 1 |
| 367 | Genetic polymorphism in CYP2D6 and cardiovascular drugs. Japanese Journal of Electrocardiology, 2006, 26, 201-210. | 0.0 | 0 |
| 369 | PHARMACOGENETICS AND PHARMACOGENOMICS. , 2009, , 219-224. | | 1 |
| 370 | Hemmstoffe fÄ¼r Oxidoreduktasen. , 2009, , 459-498. | | 0 |
| 371 | Polymorphisms of CYP and ethnic differences. Epilepsy and Seizure, 2010, 3, 141-146. | 0.1 | 0 |
| 372 | Pharmacokinetics and Pharmacogenetics in Clinical Trials. Japanese Journal of Clinical Pharmacology and Therapeutics, 2014, 45, 105-110. | 0.1 | 0 |
| 373 | Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. , 1994, 71, 197-207. | | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 374 | The impact of genetic polymorphisms in risk assessment of drugs. , 1994, 16, 211-222. | | 4 |
| 375 | Relationship between Phenotype and Genotype of CYP2C19 Using a Simplified Method for Phenotyping with Omeprazole in Healthy Japanese.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1998, 29, 495-505. | 0.1 | 0 |
| 376 | FRUIT/VEGETABLE“DRUG INTERACTIONS: PHARMACOKINETIC ASSAY WITH A CYP3A4 SUBSTRATE. World Journal of Pharmaceutical Research, 2017, , 213-224. | 0.0 | 1 |
| 377 | Pharmacogenomics in and Its Influence on Pharmacokinetics. , 2020, , 1019-1046. | | 0 |
| 379 | Metabolic capacity of CYP2D6 within an Iranian population (Mazandaran Province). Caspian Journal of Internal Medicine, 2011, 2, 213-7. | 0.1 | 1 |
| 380 | Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders. , 2021, , . | | 0 |
| 381 | Data Mining Methods as Tools for Predicting Individual Drug Response. , 0, , 379-400. | | 1 |
| 382 | Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World Journal of Clinical Oncology, 2022, 13, 712-724. | 0.9 | 1 |
| 384 | Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. Frontiers in Pharmacology, 0, 13, . | 1.6 | 3 |
| 390 | Hemmstoffe f¼r Oxidoreduktasen. , 2023, , 543-584. | | 0 |